Wednesday, January 31, 2018 4:29:24 AM
Document #: 98 Filed: 05/11/17 Page 14 of 25 PageID #:1644 State of Florida in the following manner:
1. The State of Florida shall be reimbursed for the costs and fees it incurred in this matter including its costs of investigation and litigation, after which,
2. All remaining joint funds shall be divided equally between the Commission and the State of Florida. Any money paid to the Commission not used for equitable relief shall be deposited to the U.S. Treasury as disgorgement.
SECTION VII: DISSOLUTION OF ASSET FREEZE IT IS FURTHER ORDERED that the freeze on the Stipulating Individual Defendants’ and Defendant 9138242 Canada Corporation’s assets pursuant to the Stipulated Preliminary Injunction as to Defendant Gary Oberman, entered on July 28, 2016 (Dkt. No. 52) and the Stipulated Preliminary Injunction as to Defendants BlackOptek CE Inc., 9138242 Canada Corporation, Digital Growth Properties, LLC, Muzaffar Abbas, Donald Dolphin, and Justin Powers (the “BlackOptek Preliminary Injunction”), entered on July 28, 2016 (Dkt. No. 54) is modified to permit the payments and other transfers identified in Section V above. The freeze on the Stipulating Receivership Defendants’ assets shall remain in effect until such time as the Receiver receives payment of all Court-approved fees and expenses of the Receiver and the Receiver is discharged pursuant to Section X of this Order. Upon completion of all payments and other obligations identified in in Sections V and X, the asset freeze is dissolved as to Stipulating Defendants. A financial institution 15 Case: 1:16-cv-06607 Document #: 98 Filed: 05/11/17 Page 15 of 25 PageID #:1645 shall be entitled to rely upon a letter from Plaintiffs stating that the freeze on a Stipulating Defendant’s assets has been lifted.
Recent BABL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/01/2023 09:25:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/01/2023 08:56:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/01/2023 08:41:49 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM